| PRODUCT INNOVATION | ANALYSIS
pre-clinical studies on human nails, significantly higher concentrations of the antifungal substance have been detected, compared with the concentrations measured in the nail with successful oral treatment. Like Nalox, as MOB-015 is applied locally, the side-effects associated with oral treatment are avoided. 'MOB-015 has the potential to be the
future market leader for the treatment of nail fungus,' says Mr Wolpert. He tells PRIME: 'The product is expected to be a prescription product in certain markets, as regards positioning, and will likely compete in the same markets as Nalox, but it is early days yet.' MOB-015 will be delayed from its
original launch timing, which was estimated to be 2017. A pipeline actinic keratosis (AK), genital warts and basal cell cancer product, Limtop, is likely to hit the market in 2017. Moberg Derma was recently granted SKr4 million by the funder Vinnova for the development of Limtop with a goal to initiate clinical studies in the first half of 2012. Vinnova aims to support local small and medium
enterprises (SMEs) in Sweden. Pre-clinical results show that Limtop has a far greater capacity than existing preparations when it comes to transporting the active substance to the target tissue in the skin.
Conclusions Elsewhere, now in an expansion phase, Moberg Derma has plans to ramp up staffing, and has begun by appointing a new vice president of pharmaceutical innovation and development, Lena Pereswetoff-Morath, who was formerly in a similar position at Orexo. 'She will help us maximise the tremendous opportunities
for the
innovation we are targeting. Not new molecules ® patients donÕt care about that particularly. But we want to make full use of the products in all respects, including packaging, formulation and delivery,' says the CEO. Even with growth products, SMEs have
to work hard to be noticed. 'WeÕ re too small for many investors, so we need to get them to understand the company and how it differs from a biotech or a pharma.'
He says: 'Moberg Derma is not high risk,
but we have learnt that you have to be constantly on your toes and be adaptable. We have changed our plans constantly. You have to be ready to do that. And we have learned a lot from the market. Over time our development performance will be judged. Maybe when weÕve completed 10–20 projects.' As to the future, 'we are very optimistic
about Nalox, and additionally have strong partners in place. The first productÕs success has created a platform to develop the company ® including developing products internally as well as licensing in or acquiring external assets.'
Reference
1. Haneke E. The ageing of the nails: aetiology and implications for treatment. Prime 2011; 1(2): 58–65
premium aesthetic needles & cannulas
Engineered from steel to finish.
TSK LABORATORY EUROPE B . V.
www.tsklab.com |
europe@tsklab.com Made in Japan
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112